

## **Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC**

**Leuven, BELGIUM – October 24, 2024 – 06:00 PM CET - [Oxurion NV](#)** (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation<sup>1</sup> it has received a transparency notification as follows:

Oxurion received a transparency notification on October 24, 2024, from Atlas Special Opportunities, LLC indicating that as of October 23, 2024, it held 383,105 shares of the then outstanding 2,002,550 shares, and therefore crossed under the threshold (20%) by virtue of the sale of voting securities. See Annex 1.

### **About Oxurion**

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at [www.oxurion.com](http://www.oxurion.com).

### ***Important information about forward-looking statements***

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

### **For further information please contact:**

<p><a href="#">Oxurion NV</a> Pascal Ghoson Chief Executive Officer <a href="mailto:Pascal.ghoson@oxurion.com">Pascal.ghoson@oxurion.com</a></p>
--

---

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

# ANNEX 1

1) Status of the notification

Final

2) Issuer

Name: OXURION  
 Identification number: 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights +

4) Notification by

A person that notifies alone +

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

**i** Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6 Part II

7) Date on which the threshold is crossed

23/10/2024 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

20

**i** If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

2,002,550


**i** Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	500,204	383,105	0	19.13%	0.00%
<b>TOTAL</b>		<b>383,105</b>	<b>0</b>	<b>19.13%</b>	<b>0.00%</b>

**i** Start with "groups" of holders. Add subtotals with  $\Sigma$ , and then finish with the persons who are "alone". For groups, start with the ultimate controlling natural person or legal entity. The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments	After the transaction						
	Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL					0	0.00%	

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
	CALCULATE	383,105
		19.13%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder  will cease to hold / will hold again  0 voting rights as of  (DD/MM/YYYY)

13) Additional information

On 4 October 2024 (with settlement date on 8 October 2024), Atlas Special Opportunities LLC sold 47,363 shares in Oxurion NV, as a result of which its shareholding decreased to 452,841 shares (= 22.61%, denominator = 2,002,550).  
 On 10 October 2024 (with settlement date on 14 October 2024), Atlas Special Opportunities LLC sold 10,802 shares in Oxurion NV, as a result of which its shareholding decreased to 442,039 shares (= 22.07%, denominator = 2,002,550).  
 On 14 October 2024 (with settlement date on 16 October 2024), Atlas Special Opportunities LLC sold 13,556 shares in Oxurion NV, as a result of which its shareholding decreased to 428,483 shares (= 21.40%, denominator = 2,002,550).  
 On 18 October 2024 (with settlement date on 22 October 2024), Atlas Special Opportunities LLC sold 13,227 shares in Oxurion NV, as a result of which its shareholding decreased to 415,256 shares (= 20.74%, denominator = 2,002,550).  
 On 21 October 2024 (with settlement date on 23 October 2024), Atlas Special Opportunities LLC sold 32,151 shares in Oxurion NV, as a result of which its shareholding decreased to 383,105 shares (= 19.13%, denominator = 2,002,550).

Done at  New York

On  23/10/2024 (DD/MM/YYYY)

Name & capacity  Patrick Vance, Proxyholder

Signature  

For security reasons, the unsigned form in **xlsx** format should be transmitted to [trp.fin@fma.be](mailto:trp.fin@fma.be). You can do this manually OR if you have MS Outlook at your disposal via the "Save & Send" button.

In addition, a signed copy in **PDF** format should also be transmitted.